August 31, 2026 | Latest News & Updates in Child Neurology Nursing
Precision epilepsy treatment moves toward individualized ASOs
One of the most clinically exciting recent papers is a Nature Medicine study describing individualized antisense oligonucleotides (ASOs) for children with SCN2A-related developmental epileptic encephalopathy.
The investigators developed mutation-specific ASOs designed to correct the molecular consequences of individual SCN2A variants. Importantly, the work moves beyond the concept of precision medicine toward patient-specific molecular therapy, with implications for other genetic epilepsies.
Why it matters for pediatric neuroscience nursing
- Genetic diagnosis may increasingly identify a treatable molecular mechanism, rather than simply provide an explanation.
- Nurses and APPs will increasingly be involved in education around individualized genetic therapies and longitudinal monitoring.
Key Reference
- Kim-McManus, O., Mignon, L., Douville, J., et al. (2026). Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy.
Nature Medicine, 32, 2838–2845. https://doi.org/10.1038/s41591-026-04527-y. .
What happens when the father takes valproate?
A large study published this month in Neurology examined whether paternal valproate exposure around conception is associated with neurodevelopmental disorders or congenital malformations in offspring.
Researchers analyzed more than 2.5 million children in Taiwan, including 1,701 whose fathers had been prescribed valproate during the three months before conception. After adjustment for multiple confounders—and in a sibling comparison—the investigators found no significant association between paternal valproate exposure and autism, ADHD, intellectual disability, tic disorders, or congenital malformations.
This is particularly interesting because the reproductive safety concerns surrounding valproate have historically focused heavily on maternal exposure.
Important caveat:
This study does not change the well-established concerns regarding valproate exposure during pregnancy. The authors also emphasize limitations, including variable follow-up duration and the need for additional studies in other populations.
Key Reference
- Feng, Y.-C. A., et al. (2026). Paternal valproate exposure and offspring neurodevelopmental outcomes.
Neurology. Published August 19, 2026. DOI: 10.1212/WNL.0000000000218375.
The brain environment can drive pediatric brain tumor biology
A recent Nature Neuroscience paper provides another important advance in understanding pediatric brain tumors.
Researchers identified a signaling pathway involving neuroligin-3 (NLGN3), CSPG4 and PIEZO1 that links neuronal activity with oligodendrocyte precursor cell biology and glioma proliferation. The study demonstrates that neuronal activity isn't simply something occurring around a tumor—the neural environment can actively influence tumor-cell behavior.
The finding is particularly relevant to pediatric neuro-oncology because high-grade gliomas and diffuse midline gliomas remain among the most challenging childhood brain tumors. The authors describe how gliomas can exploit mechanisms normally involved in glial plasticity and myelination.
This represents a broader shift in neuro-oncology: The tumor is not an isolated mass—it is part of a dynamic neural ecosystem.
That concept could eventually lead to treatments targeting neuron–tumor interactions, rather than tumor cells alone.
Key Reference
- Kim, Y. S., Gillespie, S. M., Geraghty, A. C., et al. (2026). Neuroligin-3–CSPG4 interaction maintains oligodendrocyte precursor cell progenitor state and promotes glioma proliferation through mechanotransduction. Nature Neuroscience. Published August 6, 2026. https://doi.org/10.1038/s41593-026-02397-8.
